Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Menu
Stocks | Futures | Watchlist | More
 
No Matching Results
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact Contact Barchart
Market:

Ocular Therapeut (OCUL)

Ocular Therapeut (OCUL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alerts
Watch
Help
Go To:
Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences Business Wire - Tue Nov 8, 2022

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...

OCUL : 4.19 (-1.41%)
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates (Revised) Zacks - Tue Nov 8, 2022

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -30.43% and 18.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

OCUL : 4.19 (-1.41%)
ALPN : 7.86 (-1.19%)
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates Zacks - Mon Nov 7, 2022

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -34.78% and 18.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

OCUL : 4.19 (-1.41%)
ALPN : 7.86 (-1.19%)
Ocular Therapeutix: Q3 Earnings Snapshot AP - Mon Nov 7, 2022

Ocular Therapeutix: Q3 Earnings Snapshot

OCUL : 4.19 (-1.41%)
Ocular Therapeutix™ Reports Third Quarter 2022 Financial Results and Business Update Business Wire - Mon Nov 7, 2022

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...

OCUL : 4.19 (-1.41%)
Ocular Therapeutix™ To Report Third Quarter 2022 Financial Results Business Wire - Mon Oct 24, 2022

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...

OCUL : 4.19 (-1.41%)
Ocular Therapeutix (OCUL) Soars 24.2%: Is Further Upside Left in the Stock? Zacks - Fri Sep 30, 2022

Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near...

OCUL : 4.19 (-1.41%)
COLL : 27.65 (-0.36%)
Ocular (OCUL) Announces Positive Data on Wet AMD Candidate Zacks - Tue Sep 27, 2022

Ocular (OCUL) interim seven-month data on OTX-TKI from a phase I study for treating wet age-related macular degeneration (wet AMD) shows a favorable safety profile, and stable and sustained visual acuity....

REGN : 764.63 (-2.08%)
BAYRY : 15.7000 (+0.26%)
OCUL : 4.19 (-1.41%)
BOLT : 1.5500 (+1.97%)
Ocular Therapeutix™ Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD Business Wire - Tue Sep 27, 2022

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...

OCUL : 4.19 (-1.41%)
Ocular Therapeutix™ To Present Data at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting Business Wire - Thu Sep 22, 2022

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...

OCUL : 4.19 (-1.41%)

Barchart Exclusives

Chart of the Day: Entravision Communications - New Beginning Barchart - Tue Feb 7, 7:00AM CST
The reason for the New Beginning headline: Entravision (NYSE: EVC ), a leading global advertising solutions, media and technology company, today announced that Walter F. Ulloa, the Company’s Chairman and Chief Executive Officer, passed away of a sudden heart attack on December 31, 2022. He was 74 years old. The... Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot